All In Biotech

Drug Trial Radar · NCT01580007

Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB)

Clinical Trial of Oral Phenylbutyrate and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis in Bangladesh: a Pilot Study

Last checked: Nov 19, 2026Latest source record: Feb 13, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 288 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

288

Actual

Start

Dec 2010

Primary completion

Dec 2014

Study completion Dec 2014

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Karolinska Institutet; National Institute of Diseases of the Chest and Hospital, Bangladesh; University of Iceland
First posted
Apr 18, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Vitamin D exerts its effects via the Vitamin D Receptor (VDR) present in activated macrophages and induces expression and release of the cathelicidin, LL-37, a human antimicrobial peptide involved in killing of MTB. We aimed to investigate whether treatment of newly diagnosed pulmonary TB patients for 2 months with adjunctive PBA and vitamin D (Cholecalciferol) in combination with standard DOTS therapy (i) can improve response to standard short course TB therapy towards a rapid recovery; (ii) can induce expression of LL-37 in macrophages; (iii) can enhance killing capacity of macrophages isolated from TB patients infected in vitro with MTB; and (iv) does not evoke any adverse effects.

Conditions

  • Pulmonary Tuberculosis

Interventions

  • Active Sodium Phenylbutyrate and active cholecalciferolDrug

    Sodium Phenylbutyrate: 500 mg twice daily orally for 2 months Cholecalciferol: 5000 IU once daily orally for 2 months

  • Placebo Sodium Phenylbutyrate plus active cholecalciferolDrug

    Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Cholecalciferol: 5000 IU once daily for 2 months

  • Active Sodium Phenylbutyrate and placebo cholecalciferolDrug

    Sodium phenylbutyrate: 500 mg twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months

  • Placebo Sodium Phenylbutyrate plus placebo cholecalciferolDrug

    Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of pulmonary TB patients who are culture negative in sputum in week 4Time frame: week 4
  2. Difference in improvement in clinical endpoints consisting of cough clearance, percentage chest x-ray clearance, fever remission and weight increase upto 8 weeks.Time frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institute of Diseases of Chest and Hospital (NIDCH)

    Dhaka, Bangladesh

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.